Humaneva Group Secures $50 Million Investment from Viking Global to Support Global Clinical Research Expansion
Tomasz Dąbrowski, CEO, Humaneva ● Photo Credit: Humaneva
WARSAW, Poland, September 30, 2024 (VSNewsNetwork.com) – Humaneva Inc., a clinical research organization, announced a $50 million investment from Viking Global Investors to further accelerate its expansion into the U.S. and Asia-Pacific regions. Viking has also secured a one-year option to invest an additional $50 million. This investment aims to support Humaneva's growth strategy, which includes mergers and acquisitions, market consolidation, and technological advancements in clinical research.
The Humaneva Group, which operates through its subsidiaries Pratia, Kapadi, and Hyggio, specializes in providing clinical trial solutions. With over 90 Clinical Trial Centers, the company is focusing on expanding its proprietary technologies, particularly in eSource solutions, data integration, and analytics to facilitate better access to clinical research.
“The clinical trials market is undergoing rapid transformation, driven by global consolidation and innovative business models. Partnering with Viking is a strategic milestone for us. Viking’s unique blend of hedge fund and private equity expertise, coupled with their long-term, value-building perspective, aligns perfectly with Humaneva's vision. The United States accounts for nearly 80% of all R&D expenditures in the clinical trials market. Strengthening our presence, especially in the U.S., will significantly expand our scale and capabilities in the coming years”, said Tomek Dabrowski, CEO of Humaneva Inc.
According to the company, Humaneva distinguishes itself with its focus on oncology, advanced data management, and proprietary technology that integrates clinical trial centers, sponsors, and CROs. Humaneva’s approach is designed to enhance trial efficiency by streamlining processes, reducing indirect tasks, and improving data consistency, which in turn reduces the time and costs associated with clinical trials.
For more information on Humaneva's projects and partnerships, visit their website.
Source: Humaneva Group
